Skip to main content
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp - Investor Relations & Filings

Listed IPO Jun 2019
Ticker · ADPT ISIN · US00650F1093 LEI · 549300ZTF7OT1FW66Q96 US Professional, scientific and technical activities
Open in API
Filings indexed 709 across all filing types
Latest filing 2026-06-22 Capital/Financing Update
Country US United States of America
Listing US ADPT · 7 venues

Key figures FY2025

Period ended 2025-12-31 · USD
Headline annual figures for Adaptive Biotechnologies Corp, fiscal year 2025, reported in USD, with the source filing for each figure.
Total Revenues USD 276.98M per the Annual Report filed 2026-02-26
Net Income USD -59.46M per the Annual Report filed 2026-02-26
Total Assets USD 512.74M per the Annual Report filed 2026-02-26
Total Equity USD 225.00M per the Annual Report filed 2026-02-26
Cash from Ops USD -45.99M per the Annual Report filed 2026-02-26

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Adaptive Biotechnologies Corp

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp. is a commercial-stage company focused on immune-driven medicine. It specializes in decoding the adaptive immune system to develop clinical products for diagnosing and treating diseases. The company operates an Immune Medicine Platform that sequences T-cell and B-cell receptors to generate immune receptor data. This data is applied across life sciences research, clinical diagnostics, and drug discovery. A key offering is clonoSEQ, a highly sensitive, next-generation sequencing (NGS) assay for assessing Minimal Residual Disease (MRD) in certain blood cancers. This product is utilized in both clinical practice and biopharmaceutical drug trials. The company aims to harness the immune system's natural capabilities as a tool to transform disease detection and treatment.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filing that reports the issuance of $345 million in aggregate principal amount of 0% Convertible Senior Notes due 2031 by Adaptive Biotechnologies Corporation. It includes detailed information about the terms of the notes, use of proceeds, the indenture, capped call transactions, a waiver agreement with OrbiMed, and related material definitive agreements. The filing also includes references to additional exhibits like the indenture and capped call confirmations. There is no indication that this document is an announcement or summary of a report such as an annual or quarterly report, nor is it an earnings release or management discussion. The content primarily relates to financing and capital structure activities. Given this detailed disclosure of financing activities, the correct classification is Capital/Financing Update (CAP). The confidence is high given the specificity and detailed nature of the financing discussion.
2026-06-22 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed under the Securities Exchange Act of 1934. It announces the company's intention to offer convertible senior notes (a financing activity) and a business separation event. It includes press releases related to these announcements as exhibits. There are no comprehensive financial statements or detailed financial analysis in the document, only disclosures of planned capital raising and structural changes. Therefore, it falls under Capital/Financing Update (CAP) as it pertains mainly to the intended offering of notes and related capital activities.
2026-06-15 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report (not an annual or quarterly report) filed pursuant to Section 13(d) of the Exchange Act. It specifically covers Item 5.07 “Submission of Matters to a Vote of Security Holders” and provides detailed vote results for the company’s annual meeting proposals. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (DVA), as it reports official shareholder voting outcomes.
2026-06-09 English
46th Annual William Blair Growth Stock Conference
Call Transcript Classification · 100% confidence
2026-06-03 English
Q1 2026
Call Transcript Classification · 100% confidence
2026-05-05 English
Adaptive Biotechnologies First Quarter Financial Results
Call Transcript Classification · 100% confidence The document is a verbatim transcript of an earnings conference call, featuring speaker names (e.g., Chad Robbins, Kyle Pisko), Q&A session instructions, and a dialogue between management and analysts regarding financial results. This matches the definition of a Call Transcript (CT).
2026-05-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.